Daxor Corporation announces two new studies validating the clinical benefits of blood volume analysis, BVA, as a more precise measurement of congestion in ambulatory heart failure patients. Data from both studies demonstrated a lack of correlation between surrogate measures and actual blood volume, highlighting the necessity for accurate volume measurement, as provided by BVA. The study titled, ‘Impact of Systemic and Pulmonary Afterload on the Pressure-Volume Relationship in Heart Failure Using Direct Blood Volume Measurement,’ was presented at the American College of Cardiology Scientific Sessions 2024. A research letter published in the American Heart Journal, titled, ‘Prognostic Implications of Volume Status Assessed by Blood Volume Analysis in Ambulatory Heart Failure,’ was authored by leading heart failure experts from Duke University Medical Center, Baptist Memorial Hospital and Banner University Medical Center.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
- Daxor announces purchase of BVA-100 at Chicago hospital
- Daxor acquires Volumex, Megatope for Iso-Tex Diagnostics
- Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
- Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
